A SIMPLE KEY FOR HEMGENIX UNVEILED

Number of qualified clients: CDEC mentioned the uncertainty in the volume of sufferers with reasonably significant to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be categorised as acquiring moderate or reasonable disease could have a severe bleed